• (02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression

  September 4, 2020

  Dual-Histamine Receptor Blockade with Cetirizine – Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients https://doi.org/10.1016/j.pupt.2020.101942 A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a… Continue reading "(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression"

• (28 Aug 2020) Famotidine- associated with a lower risk of mortality

  August 29, 2020

  Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 https://doi.org/10.14309/ajg.0000000000000832 Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 +/- 15.0… Continue reading "(28 Aug 2020) Famotidine- associated with a lower risk of mortality"

• (08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients

  May 11, 2020

  Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study https://doi.org/10.1101/2020.05.01.20086694 In a retrospective study in patients hospitalized with COVID-19  famotidine use was associated with a significantly reduced risk of clinical… Continue reading "(08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients"